Re: Currently recruiting trials from NBIX
from the last earnings call:
Turning now to our CAH program and the Phase II proof of concept study examining the pharmacokinetics, pharmacodynamics and tolerability of NBI-74788 in adult patients with classic, 21-hydroxylase deficiency. As mentioned last quarter site initiation was slower than originally planned for this study, but we now have our sites active and focused on enrollment. We anticipate that initial data from the study will be available later this quarter with the full study completed in quarter four. With these data in hand, we plan to meet with the FDA to discuss the path forward for this -- the clinical evaluation of this molecule as a novel treatment for both adults and children with Congenital Adrenal Hyperplasia.